Martin Heidecker (AMR Action Fund)

Heidecker, Martin (AMR Action Fund 202301 Chief Investment Officer before Boehringer Ingelheim Venture Fund)

	Organisation	AMR Action Fund
	Former/major organisation	Boehringer Ingelheim Venture Fund (BIVF)
	Group	Boehringer Ingelheim (Group)
	Product	venture capital
	Product 2	antibiotic

Record changed: 2023-01-05

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Martin Heidecker

[1] BioVersys AG. (1/5/23). "Press Release: BioVersys Extends Its Series C Round to CHF 32.6 Million with investment from the AMR Action Fund". Basel....
[2] AMR Action Fund. (2/7/22). "Press Release: AMR Action Fund Opens European Office". Boston, MA....
[3] Libra Therapeutics, Inc.. (9/23/20). "Press Release: Libra Launches with $29M Series A to Develop Novel Therapeutics for Neurodegenerative Diseases". San Diego, CA....
[4] Rgenta Therapeutics, Inc.. (4/2/20). "Press Release: Rgenta Therapeutics Launches with $20 Million Seed Investment". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)